These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21668917)

  • 1. "Reversible" Alzheimer's disease?
    Peter F; Susanne J; Margareta H; Silvia W; Wolfgang K; Thomas L; Heinz TK
    J Am Geriatr Soc; 2011 Jun; 59(6):1137-8. PubMed ID: 21668917
    [No Abstract]   [Full Text] [Related]  

  • 2. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.
    Kim YW; Kim DY; Shin JC; Park CI; Lee JD
    Clin Neuropharmacol; 2009; 32(2):63-8. PubMed ID: 18978490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of responders and non-responders to long-term donepezil treatment.
    Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
    Psychogeriatrics; 2010 Jun; 10(2):53-61. PubMed ID: 20738808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
    Tariot PN; Jakimovich L
    J Am Med Dir Assoc; 2003; 4(4):216-9. PubMed ID: 12837144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of donepezil in treating Alzheimer's disease.
    Garcia A
    Can Fam Physician; 1999 Aug; 45():1858-9. PubMed ID: 10463081
    [No Abstract]   [Full Text] [Related]  

  • 6. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.
    Bouwman FH; Verwey NA; Klein M; Kok A; Blankenstein MA; Sluimer JD; Barkhof F; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 30(1):1-7. PubMed ID: 20606438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
    Meguro M; Kasai M; Akanuma K; Ishii H; Yamaguchi S; Meguro K
    Age Ageing; 2008 Jul; 37(4):469-73. PubMed ID: 18515851
    [No Abstract]   [Full Text] [Related]  

  • 8. Donepezil-induced nightmares in mild cognitive impairment.
    Kitabayashi Y; Ueda H; Tsuchida H; Yamashita T; Narumoto J; Fukui K
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):123-4. PubMed ID: 16472374
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug may slow brain shrinkage in pre-Alzheimer's disease.
    Mayo Clin Health Lett; 2006 Dec; 24(12):4. PubMed ID: 17304693
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuro-ophthalmic findings in the visual variant of Alzheimer's disease.
    Lee AG; Martin CO
    Ophthalmology; 2004 Feb; 111(2):376-80; discussion 380-1. PubMed ID: 15019393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of pre-morbid IQ on Mini-Mental State Examination score at time of dementia presentation.
    Starr JM; Lonie J
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):382-4. PubMed ID: 17380476
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of neuropsychological impairment in MCI patients with small subcortical infarcts or hippocampal atrophy.
    Gainotti G; Ferraccioli M; Vita MG; Marra C
    J Int Neuropsychol Soc; 2008 Jul; 14(4):611-9. PubMed ID: 18577290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease.
    Matsuda O; Shido E; Hashikai A; Shibuya H; Kouno M; Hara C; Saito M
    Psychogeriatrics; 2010 Dec; 10(4):167-72. PubMed ID: 21159050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease.
    Chan D; Fox NC; Scahill RI; Crum WR; Whitwell JL; Leschziner G; Rossor AM; Stevens JM; Cipolotti L; Rossor MN
    Ann Neurol; 2001 Apr; 49(4):433-42. PubMed ID: 11310620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.
    Rockwood K; Black S; Bedard MA; Tran T; Lussier I;
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
    Seripa D; Bizzarro A; Pilotto A; D'onofrio G; Vecchione G; Gallo AP; Cascavilla L; Paris F; Grandone E; Mecocci P; Santini SA; Masullo C; Pilotto A
    Pharmacogenet Genomics; 2011 Apr; 21(4):225-30. PubMed ID: 20859244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving functioning in patients with Alzheimer's.
    J Psychosoc Nurs Ment Health Serv; 1998 May; 36(5):11-2. PubMed ID: 9604834
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.